Skip to main content Skip to main navigation menu Skip to site footer
International Journal of Nutrology
Review
DOI: 10.54448/ijn23204
Submitted: 03-20-2023
Published: 03-20-2023

Evidence from clinical studies of the nutrological modulation of the gut microbiota in inflammatory bowel diseases: a systematic review

Harmony Clinic, Campo Grande, Mato Grosso do Sul, Brazil
Inflammatory bowel disease Diet therapy Nutrological treatment Gut microbiota Quality of life

Abstract

Introduction: The main risk factor for inflammatory bowel disease (IBD) is a positive family history in 10-25% of patients. Crohn's disease (CD) can affect individuals from 15 to 40 years old and from 50 to 80 years old, more frequently in women. Ulcerative colitis (UC) can start at any age. The pathogenesis of IBD is linked to genetically susceptible individuals, dysregulated gut microbiota (dysbiosis), chronic inflammation, and poor dietary patterns. Diet plays an important role in modulating the gut microbiota and can be applied as a therapeutic tool to improve the course of the disease. Objective: To carry out a systematic review of the main interactions between dietary therapy, gut microbiota, and inflammatory bowel disease, to elucidate the main clinical outcomes after nutrological treatment. Methods: The present study followed the international model of systematic review (PRISMA). Clinical studies were included, involving randomized controlled, prospective, and retrospective studies published from 2010 to 2022. Results: It was founded 87 studies on diet modulation in the control of IBD. These studies showed reductions in persistent intestinal symptoms, improvement of gut microbiota, reduction of inflammation markers, and improvement in quality of life, with p<0.05 (95% CI). The studies were homogeneous (X2 = 98.9%), which increases the reliability of the clinical results on the dietary importance in the modulation of IBD. Conclusion: The important role of diet modulation in the control and even in the remission of IBD was evidenced.

Metrics

Metrics Loading ...

References

  1. Simões CD, Maganinho M, Sousa AS. FODMAPs, inflammatory bowel disease and gut microbiota: updated overview on the current evidence. Eur J Nutr. 2022 Apr;61(3):1187-1198. doi: 10.1007/s00394-021-02755-1.
  2. MINISTRY OF HEALTH/SECRETARY OF HEALTH CARE (JOINT ORDINANCE No. 14, OF NOVEMBER 28, 2017). Approves the Clinical Protocol and Therapeutic Guidelines for Crohn's Disease). Accessed February 2022.
  3. MINISTRY OF HEALTH/SECRETARY OF HEALTH CARE (CONITEC). Clinical Protocol and Therapeutic Guidelines Ulcerative Colitis. Accessed September 2022.
  4. He P, Yu L, Tian F, Zhang H, Chen W, Zhai Q. Dietary Patterns and Gut Microbiota: The Crucial Actors in Inflammatory Bowel Disease. Adv Nutr. 2022 Oct 2;13(5):1628-1651. doi: 10.1093/advances/nmac029.
  5. Metwaly A, Reitmeier S, Haller D. Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders. Nat Rev Gastroenterol Hepatol. 2022 Jun;19(6):383-397. doi: 10.1038/s41575-022-00581-2.
  6. Roda G, Chien Ng S, Kotze PG, et al. Crohn's disease [published correction appears in Nat Rev Dis Primers. 2020 Apr 6;6(1):26] [published correction appears in Nat Rev Dis Primers. 2020 May 20;6(1):42] [published correction appears in Nat Rev Dis Primers. 2020 Jun 19;6(1):51]. Nat Rev Dis Primers. 2020;6(1):22. Published 2020 Apr 2. doi:10.1038/s41572-020-0156-2.
  7. Adolph TE, Zhang J. Diet fuelling inflammatory bowel diseases: preclinical and clinical concepts. Gut. 2022 Dec;71(12):2574-2586. doi: 10.1136/gutjnl-2021326575.
  8. Inczefi O, Bacsur P, Resál T, Keresztes C, Molnár T. The Influence of Nutrition on Intestinal Permeability and the Microbiome in Health and Disease. Front Nutr. 2022 Apr 25;9:718710. doi: 10.3389/fnut.2022.718710.
  9. Green N, Miller T, Suskind D, Lee D. A Review of Dietary Therapy for IBD and a Vision for the Future. Nutrients. 2019 Apr 26;11(5). pii: E947. doi: 10.3390/nu11050947.
  10. Benjamin JL, Hedin CR, Koutsoumpas A, Ng SC, McCarthy NE, Hart AL, et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn’s disease. Gut 2011;60:923-9.
  11. Bernstein CN, Loftus EV Jr, Ng SC, Lakatos PL, Moum B; Epidemiology and Natural History Task Force of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD). Hospitalisations and surgery in Crohn’s disease. Gut 2012;61:622-9.
  12. Hanauer SB, Sandborn W; Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn’s disease in adults. Am J Gastroenterol 2001;96:635-43.
  13. Hedin C, Whelan K, Lindsay JO. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc 2007;66:307-15.
  14. Kirschner BS. Differences in the management of inflammatory bowel disease in children and adolescents compared to adults. Neth J Med 1998;53:S13-8.
  15. Landy J, Al-Hassi HO, McLaughlin SD, et al. Review article: faecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther 2011;34:409-15.
  16. Langholz E, Munkholm P, Krasilnikoff PA, Binder V. Inflammatory bowel diseases with onset in childhood: clinical features, morbidity, and mortality in a regional cohort. Scand J Gastroenterol 1997;32:139-47.
  17. Meijer BJ, Dieleman LA. Probiotics in the treatment of human inflammatory bowel diseases: update 2011. J Clin Gastroenterol 2011;45:S139-44.
  18. Shapira SN, Christofk HR. Metabolic Regulation of Tissue Stem Cells. Trends Cell Biol. 2020 Jul;30(7):566-576. doi: 10.1016/j.tcb.2020.04.004. Epub 2020 Apr 28. PMID: 32359707).
  19. Basson A. Vitamin D. Crohn’s disease in the adult patient: a review. J Parenter Enteral Nutr. 2014;38:438–58.
  20. Roth MP, Petersen GM, McElree C, Vadheim CM, Panish JF, Rotter JI. Familial empiric risk estimates of inflammatory bowel disease in Ashkenazi Jews. Gastroenterology. 1989;96(4):1016-20.
  21. Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. 2011;108(suppl 1):4615-4622.
  22. Teng F, Klinger CN, Felix KM, et al. Gut microbiota drive autoimmune arthritis by promoting differentiation and migration of Peyer’s patch T follicular helper cells. Immunity. 2016;44(4):875-888.
  23. Donohoe DR, Garge N, Zhang X, et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab. 2011;13(5):517526.
  24. Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341(6145):569-573.
  25. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571-607.
  26. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol 2009;75:7537-41.
  27. Basson A. Vitamin D. Crohn’s disease in the adult patient: a review. J Parenter Enteral Nutr. 2014;38:438–58.
  28. Xu XR, Liu CQ, Feng BS. Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2014;20:3255– 64.
  29. Adamiak T, Walkiewicz-Jedrzejczak D, Fish D, Brown C, Tung J, Khan K, et al. Incidence, clinical characteristics, and natural history of pediatric IBD in Wisconsin: a population-based epidemiological study. Inflamm Bowel Dis. 2013;19(6):1218-23.
  30. Den Besten G, Bleeker A, Gerding A, et al. Short-chain fatty acids protect against high-fat diet-induced obesity via a PPARγ-dependent switch from lipogenesis to fat oxidation. Diabetes. 2015;64(7):2398-2408.
  31. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. https://doi.org/10.1371/journal.pmed.1000097.
  32. Balshem H et al. Grade guidelines: 3 ratng the quality of evidence. Journal of Clinical Epidemiology, Maryland Heights, v. 64, n. 4, p. 401-406, 2011.
  33. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.
  34. Cox SR, Lindsay JO, Fromentin S, Stagg AJ, McCarthy NE, Galleron N, Ibraim SB, Roume H, Levenez F, Pons N, Maziers N, Lomer MC, Ehrlich SD, Irving PM, Whelan K. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial. Gastroenterology. 2020 Jan;158(1):176-188.e7. doi: 10.1053/j.gastro.2019.09.024. Epub 2019 Oct 2. PMID: 31586453.
  35. Cox SR, Prince AC, Myers CE, Irving PM, Lindsay JO, Lomer MC, Whelan K. Fermentable Carbohydrates [FODMAPs] Exacerbate Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: A Randomised, Doubleblind, Placebo-controlled, Cross-over, Re-challenge Trial. J Crohns Colitis. 2017 Dec 4;11(12):1420-1429. doi: 10.1093/ecco-jcc/jjx073.
  36. Pedersen N, Ankersen DV, Felding M, Wachmann H, Végh Z, Molzen L, Burisch J, Andersen JR, Munkholm P. Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease. World J Gastroenterol. 2017 May 14;23(18):3356-3366. doi: 10.3748/wjg.v23.i18.3356.
  37. Bodini G, Zanella C, Crespi M, Lo Pumo S, Demarzo MG, Savarino E, Savarino V, Giannini EG. A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease. Nutrition. 2019 Nov-Dec;67-68:110542. doi: 10.1016/j.nut.2019.06.023.
  38. Papada E, Amerikanou C, Torović L, Kalogeropoulos N, Tzavara C, Forbes A, Kaliora AC. Plasma free amino acid profile in quiescent Inflammatory Bowel Disease patients orally administered with Mastiha (Pistacia lentiscus); a randomised clinical trial. Phytomedicine. 2019 Mar 15;56:40-47. doi: 10.1016/j.phymed.2018.08.008.
  39. Jian L, Anqi H, Gang L, Litian W, Yanyan X, Mengdi W, Tong L. Food Exclusion Based on IgG Antibodies Alleviates Symptoms in Ulcerative Colitis: A Prospective Study. Inflamm Bowel Dis. 2018 Aug 16;24(9):1918-1925. doi: 10.1093/ibd/izy110.
  40. Albenberg L, Brensinger CM, Wu Q, Gilroy E, Kappelman MD, Sandler RS, Lewis JD. A Diet Low in Red and Processed Meat Does Not Reduce Rate of Crohn's Disease Flares. Gastroenterology. 2019 Jul;157(1):128-136.e5. doi: 10.1053/j.gastro.2019.03.015.
  41. Svolos V, Hansen R, Nichols B, Quince C, Ijaz UZ, Papadopoulou RT, Edwards CA, Watson D, Alghamdi A, Brejnrod A, Ansalone C, Duncan H, Gervais L, Tayler R, Salmond J, Bolognini D, Klopfleisch R, Gaya DR, Milling S, Russell RK, Gerasimidis K. Treatment of Active Crohn's Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition. Gastroenterology. 2019 Apr;156(5):1354-1367.e6. doi: 10.1053/j.gastro.2018.12.002.
  42. Levine A, Wine E, Assa A, Sigall Boneh R, Shaoul R, Kori M, Cohen S, Peleg S, Shamaly H, On A, Millman P, Abramas L, Ziv-Baran T, Grant S, Abitbol G, Dunn KA, Bielawski JP, Van Limbergen J. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial. Gastroenterology. 2019 Aug;157(2):440-450.e8. doi: 10.1053/j.gastro.2019.04.021.
  43. Racine A, Carbonnel F, Chan SS, Hart AR, Bueno-de-Mesquita HB, Oldenburg B, van Schaik FD, Tjønneland A, Olsen A, Dahm CC, Key T, Luben R, Khaw KT, Riboli E, Grip O, Lindgren S, Hallmans G, Karling P, Clavel-Chapelon F, Bergman MM, Boeing H, Kaaks R, Katzke VA, Palli D, Masala G, Jantchou P, Boutron-Ruault MC. Dietary Patterns and Risk of Inflammatory Bowel Disease in Europe: Results from the EPIC Study. Inflamm Bowel Dis. 2016 Feb;22(2):345-54. doi: 10.1097/MIB.0000000000000638.
  44. Braly K, Williamson N, Shaffer ML, Lee D, Wahbeh G, Klein J, Giefer M, Suskind DL. Nutritional Adequacy of the Specific Carbohydrate Diet in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2017 Nov;65(5):533538. doi: 10.1097/MPG.0000000000001613.
  45. Machado JF, Oya V, Coy CS, Morcillo AM, Severino SD, Wu C, Sgarbieri VC, Vilela MM. Whey and soy protein supplements changes body composition in patients with Crohn's disease undergoing azathioprine and anti-TNF-alpha therapy. Nutr Hosp. 2015 Apr 1;31(4):1603-10. doi: 10.3305/nh.2015.31.4.8362.
  46. Brotherton CS, Taylor AG, Bourguignon C, Anderson JG. A high-fiber diet may improve bowel function and health-related quality of life in patients with Crohn disease. Gastroenterol Nurs. 2014 May-Jun;37(3):206-16. doi: 10.1097/SGA.0000000000000047.
  47. Sökülmez P, Demirbağ AE, Arslan P, Dişibeyaz S. Effects of enteral nutritional support on malnourished patients with inflammatory bowel disease by subjective global assessment. Turk J Gastroenterol. 2014 Oct;25(5):493-507. doi: 10.5152/tjg.2014.4955.
  48. Kyaw MH, Moshkovska T, Mayberry J. A prospective, randomized, controlled, exploratory study of comprehensive dietary advice in ulcerative colitis: impact on disease activity and quality of life. Eur J Gastroenterol Hepatol. 2014 Aug;26(8):9107. doi: 10.1097/MEG.0000000000000127.
  49. Hanai H, Iida T, Takeuchi K, Arai H, Arai O, Abe J, Tanaka T, Maruyama Y, Ikeya K, Sugimoto K, Nakamura T, Nakamura K, Watanabe F. Nutritional therapy versus 6-mercaptopurine as maintenance therapy in patients with Crohn's disease. Dig Liver Dis. 2012 Aug;44(8):649-54. doi: 10.1016/j.dld.2012.03.007.
  50. Kang Y, Kim S, Kim SY, Koh H. Effect of short-term partial enteral nutrition on the treatment of younger patients with severe Crohn's disease. Gut Liver. 2015 Jan;9(1):87-93. doi: 10.5009/gnl13345.
  51. Green N, Miller T, Suskind D, Lee D. A Review of Dietary Therapy for IBD and a Vision for the Future. Nutrients. 2019 Apr 26;11(5):947. doi: 10.3390/nu11050947.
  52. Voitk AJ, Brown RA, McArdle AH, Hinchey EJ, Gurd FN. Clinical uses of an elemental diet: Preliminary studies. Can. Med. Assoc. J. 1972, 107, 123–129.
  53. Voitk AJ, Echave V, Feller JH, Brown RA, Gurd FN. Experience with elemental diet in the treatment of inflammatory bowel disease. Is this primary therapy? Arch. Surg. 1973, 107, 329–333.
  54. Ricour C, Duhamel JF, Nihoul-Fekete C. Use of parenteral and elementary enteral nutrition in the treatment of Crohn’s disease and ulcerative colitis in children. Arch. Fr. Pediatr. 1977, 34, 505–513.
  55. Navarro J, Vargas J, Cezard JP, Charritat JL, Polonovski C. Prolonged constant rate elemental enteral nutrition in Crohn’s disease. J. Pediatr. Gastroenterol. Nutr. 1982, 1, 541–546.
  56. Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J. Gastroenterol. 2011, 17, 1519–1528.
  57. Van Immerseel F, Ducatelle R, De Vos M, Boon N, Van De Wiele T, Verbeke K, Rutgeerts P, Sas B, Louis P, Flint HJ. Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease. J. Med. Microbiol. 2010, 59, 141–143.
  58. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-y M, Glickman JN, Garrett WS. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013, 341, 569–573.
  59. Thorburn AN, Macia L, Mackay CR. Diet, metabolites, and “western-lifestyle” inflammatory diseases. Immunity 2014, 40, 833–842.
  60. Chassaing B, Koren O, Goodrich JK, Poole AC, Srinivasan S, Ley RE, Gewirtz AT. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 2015, 519, 92–96.
  61. Limketkai BN, Iheozor-Ejiofor Z, Gjuladin-Hellon T, Parian A, Matarese LE, Bracewell K, MacDonald JK, Gordon M, Mullin GE. Dietary interventions for induction and maintenance of remissionin inflammatory bowel disease. Cochrane Database Syst. Rev. 2019, 2, CD012839.
  62. Knight-Sepulveda K, Kais S, Santaolalla R, Abreu MT. Diet and inflammatory bowel disease. Gastroenterol. Hepatol. 2015, 11, 511–520.
  63. Halmos EP, Gibson PR. Dietary management of IBD–insights and advice. Nat. Rev. Gastroenterol. Hepatol. 2015, 12, 133–146.
  64. Day AS, Lopez RN. Exclusive enteral nutrition in children with Crohn’s disease. World J. Gastroenterol. 2015, 2, 6809–6816.
  65. Sigall-Boneh R, Pfeffer-Gik T, Segal I, Zangen T, Boaz M, Levine A. Partial enteral nutrition with a Crohn’s disease exclusion diet is effective for induction of remission in children and young adults with Crohn’s disease. Inflamm. Bowel Dis. 2014, 20, 1353–1360.
  66. Suskind DL, Cohen SA, Brittnacher MJ, Wahbeh G, Lee D, Shaffer ML, Braly K, Hayden HS, Klein J, Gold B et al. Clinical and fecal microbial changes with diet therapy in active inflammatory bowel disease. J. Clin. Gastroenterol. 2018, 52, 155.
  67. Hart L, Farbod Y, Szamosi JC, Yamamoto M, Britz-McKibbin P, Halgren C, Zachos M, Pai N. Effect of Exclusive Enteral Nutrition and Corticosteroid Induction Therapy on the Gut Microbiota of Pediatric Patients with Inflammatory Bowel Disease. Nutrients. 2020 Jun 5;12(6):1691. doi: 10.3390/nu12061691.
  68. Zhang Y, Si X, Yang L, Wang H, Sun Y, Liu N. Association between intestinal microbiota and inflammatory bowel disease. Animal Model Exp Med. 2022 Dec;5(4):311-322. doi: 10.1002/ame2.12255.
  69. Fiorindi C, Russo E, Balocchini L, Amedei A, Giudici F. Inflammatory Bowel Disease and Customized Nutritional Intervention Focusing on Gut Microbiome Balance. Nutrients. 2022 Oct 3;14(19):4117. doi: 10.3390/nu14194117.
  70. Rajendran N, Kumar D. Role of diet in the management of inflammatory bowel disease. World J. Gastroenterol.2010, 16, 1442–1448.
  71. Quince C, Ijaz UZ, Loman N, Eren AM, Saulnier D, Russell J, Haig S, Calus S, Quick J, Barclay A. Extensive modulation of the fecal metagenome in children with crohn’s disease during exclusive enteral nutrition. Am. J. Gastroenterol. 2015, 110, 1718–1729.
  72. Ni J, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: Causation or correlation? Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 573–584.
  73. Lane ER, Lee D, Suskind DL. Dietary therapies in pediatric inflammatory bowel disease: An evolving inflammatory bowel disease paradigm. Gastroenterol. Clin. 2017, 46, 731–744.
  74. Suskind DL, Wahbeh G, Cohen SA, Damman, C.J.; Klein, J.; Braly, K.; Shaffer, M.; Lee, D. Patients perceive clinical benefit with the specific carbohydrate diet for inflammatory bowel disease. Dig. Dis. Sci. 2016, 61, 3255–3260.
  75. Suskind DL, Wahbeh G, Gregory N, Vendettuoli H, Christie D. Nutritional therapy in pediatric Crohn disease: The specific carbohydrate diet. J. Pediatr. Gastroenterol. Nutr. 2014, 58, 87–91.
  76. Kakodkar S, Farooqui AJ, Mikolaitis SL, Mutlu EA. The specific carbohydrate diet for inflammatory bowel disease: A case series. J. Acad. Nutr. Diet. 2015, 115, 1226– 1232.
  77. Cohen SA, Gold BD, Oliva S, Lewis J, Stallworth A, Koch B, Laura E, Mason D. Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 2014, 59, 516–521.
  78. Lee D, Swan CK, Suskind D, Wahbeh G, Vanamala J, Baldassano RN, Leonard MB, Lampe JW. Children with Crohn's Disease Frequently Consume Select Food Additives. Dig Dis Sci. 2018 Oct;63(10):2722-2728. doi: 10.1007/s10620-0185145-x. Epub 2018 Jun 4. PMID: 29862484; PMCID: PMC6290903.
  79. Olendzki BC, Silverstein TD, Persuitte GM, Ma Y, Baldwin KR, Cave D. An antiinflammatory diet as treatment for inflammatory bowel disease: A case series report. Nutr. J. 2014, 13, 5.
  80. Chiba M, Abe T, Tsuda H, Sugawara T, Tsuda S, Tozawa H, Fujiwara K, Imai H. Lifestyle-related disease in Crohn’s disease: Relapse prevention by a semivegetarian diet. World J. Gastroenterol. 2010, 16, 2484–2495.
  81. MacLellan A, Moore-Connors J, Grant S, Cahill L, Langille MGI, Van Limbergen J. The impact of Exclusive Enteral Nutrition (EEN) on the gut microbiome in crohn’s disease: A review. Nutrients 2017, 9, 447.
  82. Gerasimidis K, Bertz M, Hanske L, Junick J, Biskou O, Aguilera M, Garrick V, Russell RK, Blaut M, McGrogan P, Edwards CA. Decline in presumptively protective gut bacterial species and metabolites are paradoxically associated with disease improvement in pediatric Crohn’s disease during enteral nutrition. Inflamm. Bowel Dis. 2014, 20, 861–871.
  83. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat. Rev. Gastroenterol. Hepatol. 2015, 12, 205–217.
  84. Askari H, Shojaei-Zarghani S, Raeis-Abdollahi E, Jahromi HK, Abdullahi PR, Daliri K, Tajbakhsh A, Rahmati L, Safarpour AR. The Role of Gut Microbiota in Inflammatory Bowel Disease-Current State of the Art. Mini Rev Med Chem. 2022 Sep 14. doi: 10.2174/1389557522666220914093331.
  85. Lee D, Baldassano RN, Otley AR, Albenberg L, Griffiths AM, Compher C, Chen EZ, Li H, Gilroy E, Nessel L. Comparative effectiveness of nutritional and biological therapy in North American children with active crohn’s disease. Inflamm. Bowel Dis. 2015, 21, 1786–1793.
  86. Rapozo DC, Bernardazzi C, de Souza HS. Diet and microbiota in inflammatory bowel disease: The gut in disharmony. World J Gastroenterol. 2017 Mar 28;23(12):2124-2140. doi: 10.3748/wjg.v23.i12.2124.
  87. Altajar S, Moss A. Inflammatory Bowel Disease Environmental Risk Factors: Diet and Gut Microbiota. Curr Gastroenterol Rep. 2020 Oct 12;22(12):57. doi: 10.1007/s11894-020-00794-y.

How to Cite

Nunes, P. P. B. (2023). Evidence from clinical studies of the nutrological modulation of the gut microbiota in inflammatory bowel diseases: a systematic review. International Journal of Nutrology, 16(2). https://doi.org/10.54448/ijn23204